These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32968837)

  • 1. Novel Long-Acting Drug Combination Nanoparticles Composed of Gemcitabine and Paclitaxel Enhance Localization of Both Drugs in Metastatic Breast Cancer Nodules.
    Yu J; Mu Q; Perazzolo S; Griffin JI; Zhu L; McConnachie LA; Shen DD; Ho RJ
    Pharm Res; 2020 Sep; 37(10):197. PubMed ID: 32968837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis.
    Mu Q; Yu J; Griffin JI; Wu Y; Zhu L; McConnachie LA; Ho RJY
    PLoS One; 2020; 15(3):e0228557. PubMed ID: 32142553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ICAM-1 Targeted Drug Combination Nanoparticles Enhanced Gemcitabine-Paclitaxel Exposure and Breast Cancer Suppression in Mouse Models.
    Zhu L; Mu Q; Yu J; Griffin JI; Xu X; Ho RJY
    Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-Delivery of Gemcitabine and Paclitaxel in cRGD-Modified Long Circulating Nanoparticles with Asymmetric Lipid Layers for Breast Cancer Treatment.
    Zhang J; Zhang P; Zou Q; Li X; Fu J; Luo Y; Liang X; Jin Y
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30405089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker.
    Joshi A; Guo J; Holleran JL; Kiesel B; Taylor S; Christner S; Parise RA; Miller BM; Ivy SP; Chu E; Venkataramanan R; Beumer JH
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):535-545. PubMed ID: 32948918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.
    Conte PF; Gennari A; Donati S; Salvadori B; Baldini E; Bengala C; Pazzagli I; Orlandini C; Danesi R; Fogli S; Del Tacca M
    Breast Cancer Res Treat; 2001 Jul; 68(2):171-9. PubMed ID: 11688520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels.
    Moog R; Burger AM; Brandl M; Schüler J; Schubert R; Unger C; Fiebig HH; Massing U
    Cancer Chemother Pharmacol; 2002 May; 49(5):356-66. PubMed ID: 11976829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consistent efficacy and safety of gemcitabine-paclitaxel in patients with metastatic breast cancer: a retrospective comparison of East Asian and global studies.
    Xu B; Zhang XQ; Chi HD; Liu Z; Quinlivan M; Orlando M
    Asia Pac J Clin Oncol; 2014 Dec; 10(4):330-9. PubMed ID: 24175966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer.
    Fogli S; Danesi R; Gennari A; Donati S; Conte PF; Del Tacca M
    Ann Oncol; 2002 Jun; 13(6):919-27. PubMed ID: 12123338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.
    Demiray M; Kurt E; Evrensel T; Kanat O; Arslan M; Saraydaroglu O; Ercan I; Gonullu G; Gokgoz S; Topal U; Tolunay S; Tasdelen I; Manavoglu O
    Cancer Invest; 2005; 23(5):386-91. PubMed ID: 16193637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.
    Albain KS; Nag SM; Calderillo-Ruiz G; Jordaan JP; Llombart AC; Pluzanska A; Rolski J; Melemed AS; Reyes-Vidal JM; Sekhon JS; Simms L; O'Shaughnessy J
    J Clin Oncol; 2008 Aug; 26(24):3950-7. PubMed ID: 18711184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-delivery of docetaxel and gemcitabine by anacardic acid modified self-assembled albumin nanoparticles for effective breast cancer management.
    Kushwah V; Katiyar SS; Dora CP; Kumar Agrawal A; Lamprou DA; Gupta RC; Jain S
    Acta Biomater; 2018 Jun; 73():424-436. PubMed ID: 29649635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation, Characterization, and Pharmacokinetic Study of a Novel Long-Acting Targeted Paclitaxel Liposome with Antitumor Activity.
    Han B; Yang Y; Chen J; Tang H; Sun Y; Zhang Z; Wang Z; Li Y; Li Y; Luan X; Li Q; Ren Z; Zhou X; Cong D; Liu Z; Meng Q; Sun F; Pei J
    Int J Nanomedicine; 2020; 15():553-571. PubMed ID: 32158208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer.
    Shord SS; Faucette SR; Gillenwater HH; Pescatore SL; Hawke RL; Socinski MA; Lindley C
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):328-36. PubMed ID: 12721761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic.
    Papa AL; Sidiqui A; Balasubramanian SU; Sarangi S; Luchette M; Sengupta S; Harfouche R
    Cell Oncol (Dordr); 2013 Dec; 36(6):449-57. PubMed ID: 24081907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
    Logan KA; Nesbitt H; Callan B; Gao J; McKaig T; Taylor M; Love M; McHale AP; Callan JF
    Eur J Pharm Biopharm; 2021 Aug; 165():374-382. PubMed ID: 34038797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-delivery of paclitaxel and gemcitabine by methoxy poly(ethylene glycol)-poly(lactide-coglycolide)-polypeptide nanoparticles for effective breast cancer therapy.
    Dong S; Guo Y; Duan Y; Li Z; Wang C; Niu L; Wang N; Ma M; Shi Y; Zhang M
    Anticancer Drugs; 2018 Aug; 29(7):637-645. PubMed ID: 29846247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.
    Kroep JR; Giaccone G; Voorn DA; Smit EF; Beijnen JH; Rosing H; van Moorsel CJ; van Groeningen CJ; Postmus PE; Pinedo HM; Peters GJ
    J Clin Oncol; 1999 Jul; 17(7):2190-7. PubMed ID: 10561275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates.
    Perazzolo S; Shireman LM; Koehn J; McConnachie LA; Kraft JC; Shen DD; Ho RJY
    J Pharm Sci; 2018 Dec; 107(12):3153-3162. PubMed ID: 30121315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of gemcitabine/paclitaxel chemotherapy on the survival of patients with metastatic urothelial cancers.
    Matsui Y; Nishiyama H; Yoshimura K; Xing ND; Sumiyoshi T; Saito R; Inoue T; Kamba T; Ogawa O
    Int J Clin Oncol; 2013 Apr; 18(2):321-8. PubMed ID: 22410820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.